ATE550030T1 - Neue verwendung von antisekretorischem faktor - Google Patents

Neue verwendung von antisekretorischem faktor

Info

Publication number
ATE550030T1
ATE550030T1 AT04775470T AT04775470T ATE550030T1 AT E550030 T1 ATE550030 T1 AT E550030T1 AT 04775470 T AT04775470 T AT 04775470T AT 04775470 T AT04775470 T AT 04775470T AT E550030 T1 ATE550030 T1 AT E550030T1
Authority
AT
Austria
Prior art keywords
cell
condition
stem cell
disease
antisecretoric
Prior art date
Application number
AT04775470T
Other languages
English (en)
Inventor
Hans-Arne Hansson
Eva Jennische
Stefan Lange
Ivar Loennroth
Peter Eriksson
Anders Persson
Original Assignee
Faktor Ab As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Faktor Ab As filed Critical Faktor Ab As
Application granted granted Critical
Publication of ATE550030T1 publication Critical patent/ATE550030T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
AT04775470T 2003-09-26 2004-09-24 Neue verwendung von antisekretorischem faktor ATE550030T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0322645.3A GB0322645D0 (en) 2003-09-26 2003-09-26 Use of antisecretory factor peptides
PCT/SE2004/001369 WO2005030246A1 (en) 2003-09-26 2004-09-24 Novel use of antisecretory factor

Publications (1)

Publication Number Publication Date
ATE550030T1 true ATE550030T1 (de) 2012-04-15

Family

ID=29286947

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04775470T ATE550030T1 (de) 2003-09-26 2004-09-24 Neue verwendung von antisekretorischem faktor

Country Status (18)

Country Link
US (2) US20070009575A1 (de)
EP (1) EP1734989B1 (de)
JP (1) JP4943847B2 (de)
KR (1) KR101159858B1 (de)
CN (2) CN103028110B (de)
AT (1) ATE550030T1 (de)
AU (1) AU2004275682B2 (de)
BR (1) BRPI0414793A (de)
CA (1) CA2537335C (de)
DK (1) DK1734989T3 (de)
ES (1) ES2384385T3 (de)
GB (1) GB0322645D0 (de)
IL (1) IL174464A (de)
NO (1) NO340187B1 (de)
NZ (1) NZ545661A (de)
RU (1) RU2416426C2 (de)
WO (1) WO2005030246A1 (de)
ZA (1) ZA200601807B (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2472737T3 (es) * 2006-04-27 2014-07-02 Lantmnnen As-Faktor Ab Usos m�dicos adicionales de la proteína antisecretora
PL2015767T3 (pl) * 2006-04-27 2016-05-31 Lantmaennen As Faktor Ab Zastosowanie czynnika przeciwwydzielniczego do leczenia nadciśnienia śródgałkowego
EP2037950B1 (de) * 2006-04-27 2014-04-23 Lantmännen AS-Faktor AB Weitere medizinische anwendungen von antisekretorischem protein
AU2012201165B2 (en) * 2006-04-27 2013-12-19 Lantmannen As-Faktor Ab New approach to treat intraocular hypertension
US9962424B2 (en) 2007-04-27 2018-05-08 Lantmännen As-Faktor Ab Use of antisecretory factors (AF) for optimizing cellular uptake
EP3769778A1 (de) 2009-02-11 2021-01-27 Lantmännen Medical AB Verwendung von antisekretorischen faktoren (af) für optmierte zelluläre aufnahme
ITMI20120008A1 (it) * 2012-01-04 2013-07-05 Biava Maura Composizioni ad attività anti-neurodegenerativa
US9738553B2 (en) * 2012-03-16 2017-08-22 Aquatech International, Llc Process for purification of produced water
AU2013263346B2 (en) * 2012-05-18 2018-08-23 The General Hospital Corporation Methods and compositions for treating amyloid deposits
US20190192622A1 (en) * 2012-12-20 2019-06-27 Lantmännen As-Faktor Ab Use of Antisecretory Factor (AF) in Glioblastoma Treatment
WO2017009004A1 (en) 2015-07-10 2017-01-19 Lantmännen As-Faktor Ab Process for producing egg yolk with high content of af-16
WO2018015379A1 (en) 2016-07-18 2018-01-25 Lantmännen As-Faktor Ab Antisecretory factor 17
US12582697B2 (en) 2018-06-28 2026-03-24 Lantmännen Medical Ab Antisecretory factor for use in treatment and/or prevention of acute respiratory failure
WO2020065089A2 (en) 2018-09-28 2020-04-02 Lantmännen Functional Foods Ab A consumable product comprising malted dehulled oat
WO2020065091A1 (en) 2018-09-28 2020-04-02 Lantmännen Functional Foods Ab A consumable product comprising malted wheat
US20230096303A1 (en) * 2020-03-26 2023-03-30 Lantmännen Functional Foods Ab A Consumable Product Comprising Malted Cereals for Promoting Recovery at Physical Activity
CN112006035B (zh) * 2020-07-24 2021-07-30 江西新龙生物科技股份有限公司 用于防治植物病害的微生物源杀菌剂及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7566455B1 (en) * 1995-06-07 2009-07-28 Gpc Biotech, Inc. E6AP-binding proteins
SE508609C2 (sv) * 1995-08-24 1998-10-19 Rural Patent Svenska Ab Antisekretorisk faktor - dess aminosyrasekvens, nubleinsyrasekvens och användning
JP2000506375A (ja) * 1996-01-26 2000-05-30 エイチエスシー リサーチ アンド デベロップメント リミテッド パートナーシップ アルツハイマー病に関連する核酸およびタンパク質、ならびにその使用
SE513496C2 (sv) * 1998-12-17 2000-09-18 Rural Patent Svenska Ab NASP-berikad äggula samt dess användning
WO2001005968A1 (en) * 1999-06-21 2001-01-25 Inkine Pharmaceutical Company, Inc. Angiocidin: a cys-ser-val-thr-cys-gly specific tumor cell adhesion receptor
US20040072265A1 (en) * 2001-01-09 2004-04-15 Masahiro Toda Human glioma antigen and process for preparing the same
WO2003063688A2 (en) * 2002-01-25 2003-08-07 Incyte Corporation Protein modification and maintenance molecules

Also Published As

Publication number Publication date
AU2004275682B2 (en) 2010-01-28
IL174464A0 (en) 2006-08-01
US8748367B2 (en) 2014-06-10
IL174464A (en) 2015-08-31
KR101159858B1 (ko) 2012-06-25
CA2537335A1 (en) 2005-04-07
CN103028110B (zh) 2016-02-17
KR20060097718A (ko) 2006-09-14
CA2537335C (en) 2017-12-05
EP1734989B1 (de) 2012-03-21
ZA200601807B (en) 2007-06-27
EP1734989A1 (de) 2006-12-27
JP2007506735A (ja) 2007-03-22
NZ545661A (en) 2009-10-30
US20100286052A1 (en) 2010-11-11
US20070009575A1 (en) 2007-01-11
AU2004275682A1 (en) 2005-04-07
ES2384385T3 (es) 2012-07-04
CN103028110A (zh) 2013-04-10
GB0322645D0 (en) 2003-10-29
BRPI0414793A (pt) 2006-11-21
NO20060901L (no) 2006-06-20
DK1734989T3 (da) 2012-07-09
RU2416426C2 (ru) 2011-04-20
JP4943847B2 (ja) 2012-05-30
WO2005030246A1 (en) 2005-04-07
NO340187B1 (no) 2017-03-20
CN1856320A (zh) 2006-11-01
RU2006114030A (ru) 2007-11-20

Similar Documents

Publication Publication Date Title
ATE550030T1 (de) Neue verwendung von antisekretorischem faktor
Schlender et al. Interaction of measles virus glycoproteins with the surface of uninfected peripheral blood lymphocytes induces immunosuppression in vitro
Allocati et al. p63/p73 in the control of cell cycle and cell death
Zheng et al. Ginkgolide B promotes the proliferation and differentiation of neural stem cells following cerebral ischemia/reperfusion injury, both in vivo and in vitro
FI971955A7 (fi) Dopamineeristen solujen indusointi in vitro
ATE139261T1 (de) Muteine des menschlichen erythropoetins, ihre herstellung und ihre verwendung
EP1059929A4 (de) Isolierte stromalzellen zur verwendung in der behandlung von erkrankungen des zentralnervensystems
DE69839815D1 (de) Verwendung von ppar-gamma aktivatoren zur behandlung von hautkrankheiten
HUP0500477A2 (hu) Eljárások és készítmények embrionális és felnőttkori őssejtek támogatására stromasejtek alkalmazásával
DE69132352D1 (de) Protein-antagonisten der blut-koagulation und ihre verwendung
DE69823501D1 (de) Verwendung von wolinella succinogenes asparaginase zur behandlung von asparagin-abhängiger krankheiten
DE69726884D1 (de) Menschliches sdf-5 protein und diesbezügliche zusammensetzungen
DE69930662D1 (de) Humane rezeptortyrosinkinase
Mendes‐da‐Cruz et al. Neuropilins, semaphorins, and their role in thymocyte development
DE602005018683D1 (de) Herstellung von 1,4-butandiol und/oder 2-methyl 1,3-propandiol
ATE281165T1 (de) Verwendung von pramipexol zur behandlung von restless-legs-syndrom
ATE322906T1 (de) Verwendung von langem pentraxin ptx3 zur behanlung von durch geänderte aktivität des fgf-2 wachstumsfaktors hervorgerufene krankheiten
Yu et al. Double‐stranded RNA induces melanocyte death via activation of Toll‐like receptor 3
DE69916829D1 (de) Genetisch veränderte fibroblasten und ihre verwendung
DE602004030661D1 (de) Verwendung von kahalalide verbindungen zur herstellung eines arzneimittels zur behandlung von psoriasis
DE602005016680D1 (de) Verwendung von alkylfuranen zur herstellung eines antidiabetikums
ATE546154T1 (de) Anti-angiogenetisches mittel und seine verwendung bei der krebsbehandlung
ATE109509T1 (de) Anticoagulatorisches protein pp4-x, seine herstellung und verwendung.
WO2006119965A3 (en) Growth factor mutants with altered biological attributes
FI954889L (fi) Proteiini, jolla on TPO-aktiviteetti